Literature DB >> 15744229

Progress in reducing measles mortality--worldwide, 1999-2003.

.   

Abstract

Measles remains an important cause of childhood mortality, especially in developing countries. In the joint Strategic Plan for Measles Mortality Reduction, 2001-2005, the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) targeted 45 priority countries with high measles burden for implementation of a comprehensive strategy for accelerated and sustained measles mortality reduction. Components of this strategy include achieving high routine vaccination coverage (>/=90%) in every district and ensuring that all children receive a second opportunity for measles immunization. In May 2003, the World Health Assembly endorsed a resolution urging member countries to reduce deaths attributed to measles by half (compared with 1999 estimates) by the end of 2005. This report updates progress toward this goal and summarizes recent recommendations on methods to estimate global measles mortality.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15744229

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  23 in total

1.  Reversible inhibition of the fusion activity of measles virus F protein by an engineered intersubunit disulfide bridge.

Authors:  Jin K Lee; Andrew Prussia; James P Snyder; Richard K Plemper
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

2.  Epidemiological impact of a nationwide measles immunization campaign in Viet Nam: a critical review.

Authors:  Hitoshi Murakami; Nguyen Van Cuong; Hong Van Tuan; Katsuyuki Tsukamoto; Do Si Hien
Journal:  Bull World Health Organ       Date:  2008-12       Impact factor: 9.408

3.  Measles outbreaks in displaced populations: a review of transmission, morbidity and mortality associated factors.

Authors:  Isidore K Kouadio; Taro Kamigaki; Hitoshi Oshitani
Journal:  BMC Int Health Hum Rights       Date:  2010-03-19

4.  Measles deaths in Nepal: estimating the national case-fatality ratio.

Authors:  Anand B Joshi; Elizabeth T Luman; Robin Nandy; Bal K Subedi; Jayantha B L Liyanage; Thomas F Wierzba
Journal:  Bull World Health Organ       Date:  2009-06       Impact factor: 9.408

5.  Evaluation of diagnostic markers for measles virus infection in the context of an outbreak in Spain.

Authors:  María M Mosquera; Fernando de Ory; Virtudes Gallardo; Loreto Cuenca; Mercedes Morales; Waldo Sánchez-Yedra; Teresa Cabezas; Juan M Hernández; Juan E Echevarría
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 6.  The role of Toll-like receptor 4 polymorphisms in vaccine immune response.

Authors:  P Pellegrino; F S Falvella; S Cheli; C Perrotta; E Clementi; S Radice
Journal:  Pharmacogenomics J       Date:  2015-03-31       Impact factor: 3.550

7.  Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity.

Authors:  Laura K White; Jeong-Joong Yoon; Jin K Lee; Aiming Sun; Yuhong Du; Haian Fu; James P Snyder; Richard K Plemper
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

8.  Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques.

Authors:  Chien-Hsiung Pan; Nitya Nair; Robert J Adams; M Christine Zink; Eun-Young Lee; Fernando P Polack; Manmohan Singh; Derek T O'Hagan; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

9.  Two Highly Immunized Hilly Areas versus Double Measles Outbreak Investigations in District Kangra, Himachal Pradesh, India, in 2006.

Authors:  Surender N Gupta; Naveen Gupta
Journal:  J Glob Infect Dis       Date:  2009-01

10.  Double outbreak of measles in the talaja block of bhavnagar district, gujarat, India 2011: a need for improving the vaccine coverage and the community participation.

Authors:  Pankhuri P Mishra; Naresh T Chauhan
Journal:  J Clin Diagn Res       Date:  2012-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.